Seventy per cent of the people who received a booster dose of the Covid vaccine did not contract the disease during the third wave, according to a new study that covered around 6,000 people in India.
The study led by Dr Rajeev Jayadevan, co-chairman of the Indian Medical Association's national task force on coronavirus, said that 45 per cent of the vaccinated people who did not take a precautionary dose reported Covid in the third wave.
The survey covered 5,971 vaccinated people, of which 24 per cent were aged below 40 and 50 per cent belonged to the 40-59 age group.
Women accounted for 45 per cent of the people surveyed, while 53 per cent were healthcare workers.
Of the 5,971 people, 2,383 took the booster dose and 30 per cent of them reported Covid during the third wave, it said.
The boosted group also had a greater proportion of healthcare workers and higher N95 use.
The researchers also concluded that a long gap after the second dose correlated with a higher chance of infection during the third wave.
Also, "giving a third dose before a six-month gap did not make a difference in the infection rate", it said.
The study also showed that the third wave affected those aged below 40 the most -- around 45 per cent of them contracted the disease.
Around 39.6 per cent in the 40-59 age cohort and around 31.8 per cent in the 60-79 age group reported Covid during the third wave. Only 21.2 per cent of the people aged above 80 were infected.
Among the 2,311 people who were infected during the third wave, 4.8 per cent were asymptomatic while 53 per cent had mild symptoms. Moderate severity was reported by 41.5 per cent, while 0.69 per cent had severe disease.
The researchers said Covaxin and Covishield recipients had the same rate of infection in the third wave.
A total of 5,157 took Covishield and 2010 (39 per cent) of them reported Covid during the third wave of the infection. Of the 523 people who took Covaxin, 210 (40 per cent) reported Covid.
The third wave of the pandemic hit India in late December last year and subsided by March.
The government authorised a third dose of the same vaccine for healthcare and frontline workers, and the people aged above 60 from January 10 to mitigate the severity of infections, hospitalisation, and death.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)